These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23955552)

  • 1. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.
    Li YF; Zhang SF; Zhang TT; Li L; Gan W; Jia HT; Xie S; Ji HH; He DL
    Asian J Androl; 2013 Nov; 15(6):773-9. PubMed ID: 23955552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
    Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
    Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
    BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer].
    Zhang Y; Lei BH; Zou Q; Zhu QY; Lu ZJ; Wang Y
    Zhonghua Nan Ke Xue; 2017 Oct; 23(10):922-927. PubMed ID: 29727544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
    Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
    Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
    Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
    Ho TH; Nunez-Nateras R; Hou YX; Bryce AH; Northfelt DW; Dueck AC; Wong B; Stanton ML; Joseph RW; Castle EP
    Clin Genitourin Cancer; 2017 Apr; 15(2):196-202.e1. PubMed ID: 27771244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
    Hussain M; Goldman B; Tangen C; Higano CS; Petrylak DP; Wilding G; Akdas AM; Small EJ; Donnelly BJ; Sundram SK; Burch PA; Dipaola RS; Crawford ED
    J Clin Oncol; 2009 May; 27(15):2450-6. PubMed ID: 19380444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
    J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
    Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
    Chow H; Ghosh PM; deVere White R; Evans CP; Dall'Era MA; Yap SA; Li Y; Beckett LA; Lara PN; Pan CX
    Cancer; 2016 Jun; 122(12):1897-904. PubMed ID: 27019001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
    Facchini G; Caraglia M; Morabito A; Marra M; Piccirillo MC; Bochicchio AM; Striano S; Marra L; Nasti G; Ferrari E; Leopardo D; Vitale G; Gentilini D; Tortoriello A; Catalano A; Budillon A; Perrone F; Iaffaioli RV
    Cancer Biol Ther; 2010 Sep; 10(6):543-8. PubMed ID: 20657175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
    Azad AA; Beardsley EK; Hotte SJ; Ellard SL; Klotz L; Chin J; Kollmannsberger C; Mukherjee SD; Chi KN
    Invest New Drugs; 2014 Aug; 32(4):746-52. PubMed ID: 24671507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
    Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Nakabayashi M; Xie W; Buckle G; Bubley G; Ernstoff MS; Walsh W; Morganstern DE; Kantoff PW; Taplin ME
    Urology; 2013 Mar; 81(3):611-6. PubMed ID: 23452809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
    Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN
    Invest New Drugs; 2012 Aug; 30(4):1652-9. PubMed ID: 21785998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.